Medtronic gets CE mark for robot-driven vessel-sealing device
July 15, 2025
Medtronic said its market-leading LigaSure technology can now be used with its Hugo soft tissue robotic surgery system in Europe.
Medtronic said its market-leading LigaSure technology can now be used with its Hugo soft tissue robotic surgery system in Europe.
Non-Invasive Histotripsy Treatment Now Accessible to 7 Million Blue Cross Blue Shield Highmark Members Across U.S.
Next-Generation Technology Enhances Control, Safety, and Efficiency in Flexible Endoscopic Procedures
Innovative Partnership Aims to Enhance Epidural Safety with Real-Time Pressure Sensing Technology for Improved Patient Outcomes
The CE Mark approval of the VitalFlow™ ECMO System marks a significant advancement in extracorporeal life support, delivering enhanced precision and control for managing critically ill cardiac and respiratory patients.
NASHVILLE, Tenn., July 14, 2025 /PRNewswire/ — Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today unveiled new real-world U.S. physician preference data for the SOFIA™ 88 Neurovascular Support Catheter at the 2025 Society of NeuroInterventional Surgery (SNIS) Annual Meeting. The data—presented publicly for the first time —demonstrates strong performance compared to other super-bore catheters in key performance metrics such as trackability, atraumatic design and overall physician-rated experience.
“Precision medicine” has become increasingly popular in the last decade as an avenue for cancer therapy, where treatment strategies are tailored to a specific patient based on the unique characteristics of their disease and their personal background.
Researchers from Helmholtz Munich and the Technical University of Munich have developed a novel method to track cancer treatment responses in individual cells—without the need for dyes or labels.
A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of certainty years before the onset of symptoms.
A new study has revealed promising progress in developing a non-invasive sampling method to detect early signs of Parkinson’s disease—up to seven years before motor symptoms appear—by analyzing the chemical makeup of skin.